Andere talen Everest Medicines Limited

Aandelen

1952

KYG3224E1061

Vertraagde tijd Hong Kong S.E. Andere beurzen 05:59:27 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
23,35 ^HKD	+0,86%		-8,79%	+11,72%

28/03	Everest Medicines Limited rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
28/03	Transcript : Everest Medicines Limited, 2023 Earnings Call, Mar 27, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023	28/03
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	18/03
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	18/03
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024	06/03
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	27/02
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis	22/02
Everest Medicines Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine	21/02
Calliditas Year-end report, January - December 2023	21/02
Everest Medicines Announces Termination of Collaboration Agreements with Providence	19/02
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	19/02
Everest Medicines Limited Announces Board Changes	09/02
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million	22/01
Everest Foresees Surge in 2023 Revenue	22/01
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023	21/01
Everest Medicines Limited Announces Directorate Changes	12/01
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients	27/12
Everest Medicines Partner Calliditas Therapeutics Announces Nefecon the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline	22/12
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline	21/12
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China	04/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Everest Medicines Limited

Aandelen

1952

KYG3224E1061

Andere talen

Filters